Antitumor Immune Response Triggered by Metal-Based Photosensitizers for Photodynamic Therapy: Where Are We?

被引:20
作者
Jung, Alain C. [1 ,2 ]
Moinard-Butot, Fabien [1 ,3 ]
Thibaudeau, Chloe [1 ]
Gasser, Gilles [4 ]
Gaiddon, Christian [1 ]
机构
[1] Univ Strasbourg, INSERM, Lab Streinth, UMR S 1113 IRFAC, F-67200 Strasbourg, France
[2] Inst Cancerol Strasbourg Europe, Lab Biol Tumorale, F-67200 Strasbourg, France
[3] Inst Cancerol Strasbourg Europe, Dept Oncol Med, F-67200 Strasbourg, France
[4] PSL Univ, Lab Inorgan Chem Biol, Inst Chem Life & Hlth Sci, CNRS,Chim ParisTech, F-75005 Paris, France
关键词
cancer; photodynamic therapy; transition metals; immunogenic cell death; ENDOPLASMIC-RETICULUM STRESS; RU(II)-PT(II) SUPRAMOLECULE; TUMOR MICROENVIRONMENT; RUTHENIUM COMPLEXES; DNA-BINDING; CELL-DEATH; CANCER; BIODISTRIBUTION; CYTOTOXICITY; LIGHT;
D O I
10.3390/pharmaceutics13111788
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Metal complexes based on transition metals have rich photochemical and photophysical properties that are derived from a variety of excited state electronic configurations triggered by visible and near-infrared light. These properties can be exploited to produce powerful energy and electron transfer processes that can lead to oxygen-(in)dependent photobiological activity. These principles are the basis of photodynamic therapy (PDT), which is a clinically approved treatment that offers a promising, effective, and noninvasive complementary treatment or even an alternative to treat several types of cancers. PDT is based on a reaction involving a photosensitizer (PS), light, and oxygen, which ultimately generates cytotoxic reactive oxygen species (ROS). However, skin photosensitivity, due to the accumulation of PSs in skin cells, has hampered, among other elements, its clinical development and application. Therefore, these is an increasing interest in the use of (metal-based) PSs that are more specific to tumor cells. This may increase efficacy and corollary decrease side-effects. To this end, metal-containing nanoparticles with photosensitizing properties have recently been developed. In addition, several studies have reported that the use of immunogenic/immunomodulatory metal-based nanoparticles increases the antitumor efficacy of immune-checkpoint inhibitor-based immunotherapy mediated by anti-PD-(L)1 or CTLA-4 antibodies. In this review, we discuss the main metal complexes used as PDT PSs. Lastly, we review the preclinical studies associated with metal-based PDT PSs and immunotherapies. This therapeutic association could stimulate PDT.
引用
收藏
页数:17
相关论文
共 102 条
[1]   Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future [J].
Alzeibak, Razan ;
Mishchenko, Tatiana A. ;
Shilyagina, Natalia Y. ;
Balalaeva, Irina V. ;
Vedunova, Maria V. ;
Krysko, Dmitri V. .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (01)
[2]   Light activation of cyclometalated ruthenium complexes drives towards caspase 3 dependent apoptosis in gastric cancer cells [J].
Andres Solis-Ruiz, Jorge ;
Barthe, Anais ;
Riegel, Gilles ;
Omar Saavedra-Diaz, Rafael ;
Gaiddon, Christian ;
Le Lagadec, Ronan .
JOURNAL OF INORGANIC BIOCHEMISTRY, 2020, 208
[3]   DNA binding and photocleavage in vitro by new dirhodium(II) dppz complexes: Correlation to cytotoxicity and photocytotoxicity [J].
Angeles-Boza, AM ;
Bradley, PM ;
Fu, PKL ;
Wicke, SE ;
Bacsa, J ;
Dunbar, KR ;
Turro, C .
INORGANIC CHEMISTRY, 2004, 43 (26) :8510-8519
[4]   Photocytotoxicity of a new Rh2(II,II) complex:: Increase in cytotoxicity upon irradiation similar to that of PDT agent hematoporphyrin [J].
Angeles-Boza, AM ;
Bradley, PM ;
Fu, PKL ;
Shatruk, M ;
Hilfiger, MG ;
Dunbar, KR ;
Turro, C .
INORGANIC CHEMISTRY, 2005, 44 (21) :7262-7264
[5]   Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial [J].
Arits, Aimee H. M. M. ;
Mosterd, Klara ;
Essers, Brigitte A. B. ;
Spoorenberg, Eefje ;
Sommer, Anja ;
De Rooij, Michette J. M. ;
van Pelt, Han P. A. ;
Quaedvlieg, Patricia J. F. ;
Krekels, Gertruud A. M. ;
van Neer, Pierre A. F. A. ;
Rijzewijk, Joris J. ;
van Geest, Adrienne J. ;
Steijlen, Peter M. ;
Nelemans, Patty J. ;
Kelleners-Smeets, Nicole W. J. .
LANCET ONCOLOGY, 2013, 14 (07) :647-654
[6]   Padeliporfi n vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial [J].
Azzouzi, Abdel-Rahmene ;
Vincendeau, Sebastien ;
Barret, Eric ;
Cicco, Antony ;
Kleinclauss, Francois ;
van der Poel, Henk G. ;
Stief, Christian G. ;
Rassweiler, Jens ;
Salomon, Georg ;
Solsona, Eduardo ;
Alcaraz, Antonio ;
Tammela, Teuvo T. ;
Rosario, Derek J. ;
Gomez-Veiga, Francisco ;
Ahlgren, Goran ;
Benzaghou, Fawzi ;
Gaillac, Bertrand ;
Amzal, Billy ;
Debruyne, Frans M. J. ;
Fromont, Gaelle ;
Gratzke, Christian ;
Emberton, Mark .
LANCET ONCOLOGY, 2017, 18 (02) :181-191
[7]   Photodynamic Efficiency: From Molecular Photochemistry to Cell Death [J].
Bacellar, Isabel O. L. ;
Tsubone, Tayana M. ;
Pavani, Christiane ;
Baptista, Mauricio S. .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2015, 16 (09) :20523-20559
[8]   Why are there hotspot mutations in the TP53 gene in human cancers? [J].
Baugh, Evan H. ;
Ke, Hua ;
Levine, Arnold J. ;
Bonneau, Richard A. ;
Chan, Chang S. .
CELL DEATH AND DIFFERENTIATION, 2018, 25 (01) :154-160
[9]  
BEAR JL, 1975, CANCER CHEMOTH REP 1, V59, P611
[10]   Approaching tumour therapy beyond platinum drugs Status of the art and perspectives of ruthenium drug candidates [J].
Bergamo, A. ;
Gaiddon, C. ;
Schellens, J. H. M. ;
Beijnen, J. H. ;
Sava, G. .
JOURNAL OF INORGANIC BIOCHEMISTRY, 2012, 106 (01) :90-99